ID临床医生需要了解的关于丁丙诺啡治疗阿片类物质使用障碍的知识。
What the ID Clinician Needs to Know About Buprenorphine Treatment for Opioid Use Disorder.
作者信息
Westlake Amanda A, Eisenberg Mark P
机构信息
Department of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts.
Department of Medicine, Massachusetts General Hospital, Charlestown Healthcare Center. Charlestown, Massachusetts.
出版信息
Open Forum Infect Dis. 2016 Dec 27;4(1):ofw251. doi: 10.1093/ofid/ofw251. eCollection 2017 Winter.
Abstract
In the context of an escalating opioid epidemic, infectious disease clinicians increasingly treat the infectious complications of injection drug use. In this learning unit, we review the history, pharmacology, and clinical use of buprenorphine as maintenance therapy for opioid use disorder, and we describe the process by which clinicians can obtain a buprenorphine waiver.
摘要
在阿片类药物流行不断升级的背景下，传染病临床医生越来越多地治疗注射吸毒的感染性并发症。在本学习单元中，我们回顾丁丙诺啡作为阿片类药物使用障碍维持治疗的历史、药理学和临床应用，并描述临床医生获得丁丙诺啡豁免的过程。
相似文献
1
What the ID Clinician Needs to Know About Buprenorphine Treatment for Opioid Use Disorder.ID临床医生需要了解的关于丁丙诺啡治疗阿片类物质使用障碍的知识。
Open Forum Infect Dis. 2016 Dec 27;4(1):ofw251. doi: 10.1093/ofid/ofw251. eCollection 2017 Winter.
2
Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.最近获准开具丁丙诺啡用于治疗阿片类药物使用障碍的临床医生的特征和处方实践。
Addiction. 2019 Mar;114(3):471-482. doi: 10.1111/add.14436. Epub 2018 Oct 15.
3
Geographic and specialty distribution of US physicians trained to treat opioid use disorder.接受过治疗阿片类药物使用障碍培训的美国医生的地理分布和专业分布。
Ann Fam Med. 2015 Jan-Feb;13(1):23-6. doi: 10.1370/afm.1735.
4
Buprenorphine Therapy for Opioid Use Disorder.阿片类物质使用障碍的丁丙诺啡治疗。
Am Fam Physician. 2018 Mar 1;97(5):313-320.
5
Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.美国成瘾医学学会共识专家组关于在基于办公室的阿片类药物成瘾治疗中使用丁丙诺啡的声明。
J Addict Med. 2011 Dec;5(4):254-63. doi: 10.1097/ADM.0b013e3182312983.
6
Why aren't physicians prescribing more buprenorphine?为什么医生没有开出更多的丁丙诺啡？
J Subst Abuse Treat. 2017 Jul;78:1-7. doi: 10.1016/j.jsat.2017.04.005. Epub 2017 Apr 12.
7
Perioperative Pain and Addiction Interdisciplinary Network (PAIN): protocol of a practice advisory for the perioperative management of buprenorphine using a modified Delphi process.围手术期疼痛和成瘾跨学科网络（PAIN）：使用改良 Delphi 法制定围手术期丁丙诺啡管理实践指南的方案。
BMJ Open. 2019 May 22;9(5):e027374. doi: 10.1136/bmjopen-2018-027374.
8
Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.持 DEA 豁免权开具丁丙诺啡用于治疗阿片类药物使用障碍的提供者的地理分布：5 年更新。
J Rural Health. 2019 Jan;35(1):108-112. doi: 10.1111/jrh.12307. Epub 2018 Jun 20.
9
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.接受丁丙诺啡、美沙酮或纳曲酮维持治疗的阿片类物质使用障碍患者的围手术期注意事项
Anesthesiol Clin. 2018 Sep;36(3):345-359. doi: 10.1016/j.anclin.2018.04.002. Epub 2018 Jul 11.
10
A call to maximize impact of the SUPPORT for Patients and Communities Act through standard inclusion of opioid use disorder treatment curricula in medical schools.呼吁通过在医学院校标准纳入阿片类物质使用障碍治疗课程，来最大化《支持患者和社区法案》的影响。
Adv Med Educ Pract. 2019 Aug 2;10:581-583. doi: 10.2147/AMEP.S205946. eCollection 2019.
引用本文的文献
1
Common Bacterial Infections in Persons Who Inject Drugs.注射吸毒者中的常见细菌感染
Medicines (Basel). 2025 Mar 28;12(2):8. doi: 10.3390/medicines12020008.
2
Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases.超越抗生素：传染病医生在合并感染性疾病情况下治疗阿片类物质使用障碍的实用指南。
Open Forum Infect Dis. 2019 Dec 24;7(1):ofz539. doi: 10.1093/ofid/ofz539. eCollection 2020 Jan.
本文引用的文献
1
Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment.医生使用丁丙诺啡辅助治疗阿片类物质使用障碍的能力。
JAMA. 2016 Sep 20;316(11):1211-1212. doi: 10.1001/jama.2016.10542.
2
From AIDS to Opioids - How to Combat an Epidemic.从艾滋病到阿片类药物——如何抗击流行病。
N Engl J Med. 2016 Sep 1;375(9):813-5. doi: 10.1056/NEJMp1604223.
3
Treatment of Opioid-Use Disorders.阿片类物质使用障碍的治疗
N Engl J Med. 2016 Jul 28;375(4):357-68. doi: 10.1056/NEJMra1604339.
4
Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.阿片类药物依赖治疗对致命性药物相关中毒的影响：一项在英格兰开展的全国队列研究
Addiction. 2016 Feb;111(2):298-308. doi: 10.1111/add.13193. Epub 2015 Nov 25.
5
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.阿片类药物依赖管理的新进展：聚焦于舌下含服丁丙诺啡 - 纳洛酮
Subst Abuse Rehabil. 2015 Jan 6;6:1-14. doi: 10.2147/SAR.S45585. eCollection 2015.
6
Abuse and diversion of buprenorphine sublingual tablets and film.丁丙诺啡舌下片和贴膜的滥用与转移。
J Subst Abuse Treat. 2014 Jul;47(1):27-34. doi: 10.1016/j.jsat.2014.02.003. Epub 2014 Mar 3.
7
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.在一项多中心试验中，随机接受丁丙诺啡/纳洛酮治疗的患者与接受美沙酮治疗的患者相比，治疗保留率情况。
Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.
8
Oral substitution treatment of injecting opioid users for prevention of HIV infection.对注射阿片类药物使用者进行口服替代治疗以预防艾滋病毒感染。
Cochrane Database Syst Rev. 2011 Aug 10(8):CD004145. doi: 10.1002/14651858.CD004145.pub4.
9
Buprenorphine: the basic pharmacology revisited.丁丙诺啡：重新审视基本药理学。
J Addict Med. 2007 Jun;1(2):68-72. doi: 10.1097/ADM.0b013e31806c9202.
10
The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment.SUMMIT 试验：丁丙诺啡与美沙酮维持治疗的现场比较。
J Subst Abuse Treat. 2010 Dec;39(4):340-52. doi: 10.1016/j.jsat.2010.07.009.
Zotero 插件